MicroPort Scientific : ® Releases the Latest Clinical Data of TARGET Series S...

Paris, France - On May 17, Shanghai MicroPort Medical (Group) Co., Ltd. ('MicroPort') hosted a satellite meeting of 'Firehawk TARGET Series Clinical Trial Program' at EuroPCR in Paris, and released the clinical data of Firehawk Rapamycin Target Eluting Coronary Stent System ('Firehawk') Clinical Trials TARGET All Comer, TARGET I and TARGET II.

The satellite meeting was chaired by Professor William Wijns, M.D., PhD, National University of Ireland Galway, Ireland,, who is the president of EuroPCR, and Dr. Martin B. Leon of Columbia University in the City of New York. Dr. Martin B. Leon introduced the global clinical trial programs of Firehawk including the completed TARGET series in China, the undergoing TARGET All Comer Clinical Trial in Europe, and the TARGET DAPT Trial and TARGET SAFE Trial short-range dual antiplatelet therapy program that will be launched in the near future. Dr. Andreas Baumbach of Queen Mary University of London shared some cases of TARGET All Comer Trial. Afterwards, Professor William Wijns announced the three-month Optical Computerized Tomography ('OCT') data from the TARGET All Comer trial which demonstrated early vessel healing treated with Firehawk and showed non-inferiority results compared to Xience family stents. The mean neointimal thickness was 75.5μm for Firehawk and 82.3μm for Xience (P non-inferiority <0.001, with a 90% two-sided confidence interval). This good result is also supported by a percentage of malapposed and uncovered struts of 0.0% (for Firehawk and Xience arms).

Professor Bo Xu of Fuwai Hospital of Chinese Academy of Medical Sciences released the five-year follow-up data of TARGET I and TARGET II randomized clinical trials, and the result full demonstrated Firehawk has excellent early vessel healing and long-term safety and efficacy. In the TARGET I Clinical Trial, when treating simple lesions, the five-year target lesion failure ('TLF') of Firehawk and Xience arms stood at 5.7% and 6.6% respectively which no significant difference between the two arms. In the TARGET II Clinical Trial, when treating moderate-risk lesions, the five-year TLF of Firehawk was merely 8.1%. More importantly, in the TARGET I Clinical Trial, the five-year thrombosis rate of Firehawk was zero, and in the TARGET II Clinical Trial, the five-year thrombosis rate of Firehawk was 0.7%. Both of the results demonstrated the safety and efficacy in long-term clinical trials. The experts of presidium at EuroPCR said the innovative Firehawk is one of the best drug-eluting stents in PCI treatment.

In addition, during the meeting of releasing the OCT/IVUS imaging results on May 18, Dr. Andreas Baumbach once again shared the three-month OCT data from the TARGET All Comer Trial, which showed Firehawk has superior results in terms of acute gain data.

The revolutionary third-generation DES Firehawk is the result of eight years of research and development of MicroPort and it is the world's first and only target eluting stent. As the world's lowest drug dosage stent, Firehawk combines the merits of the bare metal stent and DES. It adopts unique in-groove abluminal coating design and target-eluting technology, which allow Firehawk to achieve the same clinical efficacy with significantly low drug loading, benefiting vascular early healing.

About MicroPort

MicroPort Scientific Corporation (the 'Group') is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 15 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to: www.microport.com

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words 'believe', 'intend', 'expect', anticipate', 'project', 'estimate', 'predict', 'is confident', 'has confidence' and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort's management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 2017 MicroPort Scientific Corporation